1. P44 Dupilumab reduces exacerbations and improves lung function in uncontrolled, moderate-to-severe asthma patients regardless of prior exacerbation history in the phase 3 LIBERTY ASTHMA QUEST study. (December 2018) Authors: Pavord, I; Ford, LB; Corren, J; Kuna, P; Dong, Q; Staudinger, H; Maroni, J; Rowe, P; Rout, R; Amin, N; Akinlade, B; Graham, NMH; Teper, A Journal: Thorax Issue: Volume 73(2018)Supplement 4 Page Start: A121 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗